The only drawback I can see is the high Foreign tax withholding on dividends. Howvever they seem to increase the dividends (on average) more than that tax amounts to anyway. Low debt, high growth, relatively high barrier to entry for competition, and the largest benefactor (from what I can tell) from the secular growth of diabetes in the US and worldwide. I would buy more if I hadn't completed my position last summer.
Why doesn't anyone pay attention to Cardium's Excellagen, the best diabetic foot/wound care product nobody has ever heard of? What a great acquisition that product would be for Novo! Yep, a cheap pump, but a very legitimate one.